Physician profile
Debra Rice
NPI 1770519142
$1,599.30
in general payments reported to CMS, 2019-2025
17 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $174 · 2021: $289 · 2022: $362 · 2023: $136 · 2024: $246 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $420.91 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $242.15 | 2019-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $158.37 | 2021-2022 | |
| Abbott Laboratories | $148.99 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $106.41 | 2020-2024 | Jardiance |
| Amarin Pharma, INC. | $106.01 | 2019 | |
| Abbvie INC. | $96.81 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $90.44 | 2020-2023 | Pifeltro, Delstrigo |
| Sanofi-Aventis U.S. LLC | $65.92 | 2019-2023 | |
| Pfizer INC. | $51.50 | 2019-2025 | |
| Cvrx, INC. | $22.81 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $17.94 | 2025 | Watchman Access System |
| Gilead Sciences, INC. | $16.12 | 2024 | |
| Averitas Pharma INC. | $15.61 | 2023 | Qutenza |
| Ironwood Pharmaceuticals, INC | $14.55 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.52 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.